Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Pre-ferred compositions comprise an α adrenergic receptor agonist selected from selective α1 adrenergic receptor agonist, selective α2 adrenergic receptor agonist, non-selective α1/ α2 adrenergic receptor agonist, agents with α2 adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.
